Merck Stock Climbs Near 52-Week High as BofA and ScotiaBank Lift Price Targets

By TrendSpider Editor

Merck & Company, Inc. (MRK) is gaining ground on Thursday, July 2, rising 2.84% to $128.97 as two Wall Street firms reaffirm their bullish stances and raise price targets, with ScotiaBank's Louise Chen lifting her target to $155. The stock is pressing toward its 52-week high of $130.29, a sharp reco

Merck Stock Climbs Near 52-Week High as BofA and ScotiaBank Lift Price Targets

Merck & Company, Inc. (MRK) is gaining ground on Thursday, July 2, rising 2.84% to $128.97 as two Wall Street firms reaffirm their bullish stances and raise price targets, with ScotiaBank's Louise Chen lifting her target to $155. The stock is pressing toward its 52-week high of $130.29, a sharp recovery from the 52-week low of $76.67 that puts the current price well into the upper end of its annual range. Both actions signal growing institutional conviction ahead of what has been a pivotal stretch for the pharmaceutical giant.

Key Drivers of the MRK Stock Move

• Main Catalyst: Bank of America's Tim Anderson confirmed a "buy" rating on MRK and raised his price target to $141 from $130, while ScotiaBank's Louise Chen also confirmed "buy" and lifted her target to $155 from $136, marking the larger of the two increases at $19.
• Bull Case: The average price target across both actions stands at $148, representing meaningful upside from the current price of $128.97. ScotiaBank's $155 target implies roughly 20% potential appreciation from current levels, and both firms independently arriving at higher targets on the same session reinforces the strength of the underlying thesis.
• Bear Case: Neither action is a fresh upgrade, meaning both analysts already had "buy" ratings in place. With MRK trading at $128.97 and the 52-week high just overhead at $130.29, the stock faces a clear technical ceiling. A failure to break through that level could trigger near-term profit taking, especially if broader market conditions soften heading into the holiday-shortened week.

Merck's approach to the top of its 52-week range comes at a meaningful moment. The stock spent a significant portion of the past year well below current levels, bottoming at $76.67, and the dual target raises suggest analysts see the recent recovery as fundamentally supported rather than purely technical. The $148 average price target from today's two actions gives investors a potential medium-term benchmark, and the fact that both firms are raising from already elevated prior targets indicates that fundamental estimates have been moving higher. With no downgrades among the two actions and the stock within striking distance of a 52-week breakout, sentiment is constructive heading into the back half of 2026.

MRK Analyst Ratings and Price Targets

• Bank of America (Tim Anderson): Confirms "buy" rating | Price target raised to $141 from $130
• ScotiaBank (Louise Chen): Confirms "buy" rating | Price target raised to $155 from $136

The consensus across today's two actions reflects a uniform bullish stance with zero downgrades out of two total actions. The average price target from these two firms is $148, sitting above the current price of $128.97 and the 52-week high of $130.29.

MRK Seasonality

Pharmaceutical stocks have historically shown relative stability during the early July period as investors reposition ahead of mid-year earnings season, which can create a constructive backdrop for names approaching technical breakouts. A confirmed move above the 52-week high heading into summer earnings season could attract additional momentum-driven interest.

MRK Relative Performance

With MRK up 2.84% on the session and trading at $128.97, the stock is outperforming on a day when dual analyst affirmations are providing a clear single-stock catalyst. The proximity to the 52-week high of $130.29 distinguishes MRK from many large-cap pharma peers and underscores the degree to which the stock has rebuilt value after touching the 52-week low of $76.67, a range spanning more than $53 over the past year.